Loading news...
Revvity, Inc. (RVTY) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Raymond James 47th Annual Institutional Investors Conference Monday, March 2, 2026 7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 46th Annual Health Care Conference Tuesday, March 3, 2026 2:30 p.m. ET - Prahlad Singh, president and chief executive officer Barclays 28th Annual Global Healthcare Conference Tuesday, March 10,.
WALTHAM, Mass.--(BUSINESS WIRE)-- #LifeSciences--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation, alongside other recently introduced solutions spanning sample preparation,.
Diagnostics is driving Revvity, Inc. growth, especially outside China. Signals software a standout: high-teens growth, SaaS ARR +40%. China immunodiagnostics and NIH funding remain key drags.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Revvity Inc. (NYSE: RVTY) on Monday reported better-than-expected earnings for the fourth quarter.
Adjusted EPS: $5.06 for the full year, surpassing initial guidance.Organic Growth: 3% for the year, within original guidance range.Diagnostic Segment Organic G
Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript
Revvity's (RVTY) stock is trading lower despite achieving its largest EPS upside in the past five quarters. The company reported a revenue growth of 5.9% year-o
RVTY stock climbs after Q4 adjusted EPS of $1.70 top estimates with revenue improving 5.9% to $772.1 million.
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Revvity (RVTY) came out with quarterly earnings of $1.7 per share, beating the Zacks Consensus Estimate of $1.63 per share. This compares to earnings of $1.42 per share a year ago.
Medical equipment maker Revvity handily beat fourth-quarter estimates and forecast 2026 revenue and profit above Wall Street expectations on Monday, betting on continued strength in its diagnostics business even as weakness in academic research funding persists.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for t.
RVTY's Q4 results are likely to benefit from early demand recovery signs in Life Sciences, but China Diagnostics headwinds may limit earnings upside.
Besides Wall Street's top-and-bottom-line estimates for Revvity (RVTY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from disco.
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Universal Beteiligungs und Servicegesellschaft mbH cut its position in Revvity Inc. (NYSE: RVTY) by 21.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 90,911 shares of the company's stock after selling 24,911 shares during the period. Universal
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.